We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXP icon
201
American Express
AXP
$240B
$308K 0.01%
3,600
– –
WAB icon
202
Wabtec
WAB
$43.8B
$308K 0.01%
6,400
– –
TCOM icon
203
Trip.com Group
TCOM
$27.8B
$307K 0.01%
13,100
– –
STZ icon
204
Constellation Brands
STZ
$22.9B
$295K 0.01%
2,059
– –
ST icon
205
Sensata Technologies
ST
$6.48B
$286K 0.01%
9,900
– –
SBUX icon
206
Starbucks
SBUX
$119B
$285K 0.01%
4,334
– –
AZPN
207
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$285K 0.01%
3,000
– –
LYV icon
208
Live Nation Entertainment
LYV
$42.1B
$282K 0.01%
6,200
– –
BKNG icon
209
Booking.com
BKNG
$139B
$269K 0.01%
5,000
– –
AVNT icon
210
Avient
AVNT
$3.31B
$258K 0.01%
13,600
– –
BLKB icon
211
Blackbaud
BLKB
$1.5B
$228K ﹤0.01%
4,107
– –
IQV icon
212
IQVIA
IQV
$34B
$205K ﹤0.01%
+1,900
New +$271K
KOS icon
213
Kosmos Energy
KOS
$1.36B
$54K ﹤0.01%
60,000
– –
CVET
214
DELISTED
Covetrus, Inc. Common Stock
CVET
$12K ﹤0.01%
1,520
– –
BIIB icon
215
CALL
Biogen
BIIB
$29.5B
$7K ﹤0.01%
160
– –
ALKS icon
216
Alkermes
ALKS
$8.62B
– –
-168,400
Closed -$3.44M
AMRX icon
217
Amneal Pharmaceuticals
AMRX
$5.59B
– –
-300,000
Closed -$1.45M
AUTL
218
Autolus Therapeutics
AUTL
$373M
– –
-62,200
Closed -$821K
BIB icon
219
ProShares Ultra NASDAQ Biotechnology
BIB
$81.3M
– –
-25,000
Closed -$1.54M
BPMC
220
DELISTED
Blueprint Medicines
BPMC
– –
-20,200
Closed -$1.62M
HSIC icon
221
Henry Schein
HSIC
$9.82B
– –
-5,948
Closed -$397K
LGND icon
222
Ligand Pharmaceuticals
LGND
$5.89B
– –
-24,847
Closed -$1.62M
LIVN icon
223
LivaNova
LIVN
$4.35B
– –
-126,639
Closed -$9.55M
MRK icon
224
Merck
MRK
$307B
– –
-31,440
Closed -$2.73M
VTRS icon
225
Viatris
VTRS
$19.8B
– –
-80,000
Closed -$1.61M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.